Analysed ENVVENO MEDICAL CORP (NVNO:NASDAQ) News Sources
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
07-05-2026
yahoo.com
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
07-07-2026
yahoo.com
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
15-07-2026
yahoo.com
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
31-07-2026
yahoo.com
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
27-08-2026
yahoo.com
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
16-09-2026
yahoo.com
enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
02-10-2026
yahoo.com
What is the current price of ENVVENO MEDICAL CORP (NVNO:NASDAQ)?
The current price of ENVVENO MEDICAL CORP (NVNO:NASDAQ) is $6.71.
ENVVENO MEDICAL CORP (NVNO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENVVENO MEDICAL CORP (NVNO:NASDAQ) since the previous trading day is $0.06.
ENVVENO MEDICAL CORP (NVNO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENVVENO MEDICAL CORP (NVNO:NASDAQ) since the previous trading day is 0.9023%.
What is the most recent average sentiment score for ENVVENO MEDICAL CORP (NVNO:NASDAQ)?
The most recent average sentiment score for ENVVENO MEDICAL CORP (NVNO:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ENVVENO MEDICAL CORP (NVNO:NASDAQ)?
The most recent sentiment for ENVVENO MEDICAL CORP (NVNO:NASDAQ) is .
SEC-8K** Filing Available For ENVVENO MEDICAL CORP (NVNO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.